Some tips on 3779-42-8

3779-42-8, The synthetic route of 3779-42-8 has been constantly updated, and we look forward to future research findings.

3779-42-8, 3-Bromo-N,N,N-trimethylpropan-1-aminium bromide is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a vigorously-stirred suspension of Compound 5 (80 mg, 0.14 mmol) and K2CO3 (230 mg, 1.7 mmol) in DMF (30 mL) is added (1- bromopropyl) -trimethylammonium bromide (0.3 g, 16.6 mmol) at 50 C. The mixture is stirred at this temperature for 18 h. After removal of the DMF under reduced pressure, the residue obtained is dissolved in methanol (5 mL) and filtered through a pad of silica gel (depth 2 cm) supported on a steel frit (diameter 3.5 cm). After washing the pad with methanol (ca. 1L) the crude product is eluted with acetic acid: methanol: water (3: 2: 1, by vol. ). Appropriate fractions are collected and, after evaporation of the solvent under reduced pressure, the residue obtained is purified by chromatography on a column (2.5 x 40 cm) of Sephadex LH-20 eluting with n-butanol: water: acetic acid (5: 4: 1, by vol., upper phase). After removal of the solvent from appropriate fractions under reduced pressure, the residue obtained is dissolved in methanol (5 mL) and the solution is passed through a short column (3.5 x 20 cm) of anion exchange resin (Amberlite IRA 400, chloride form). After collection of the eluate, solvent is removed under reduced pressure and the residue obtained is dried under high vacuum to yield the dichloride salt as violet crystals. 1H-NMR : 6H (300MZ, CD30D) : 0.75 (T, 3J7. 5 Hz, 3 H), 1.05-1. 20 (m, 14 H), 1.45- 1.50 (m, 2 H), 2.05-2. 15 (m, 4 H), 2.15-2. 20 (m, 2 H), 2.95 (s, 18 H), 3.35-3. 45 (m, 4 H), 3.95 (T, 3J7. 5 Hz, 4 H), 4.55 (t, 3J7. 5 Hz, 2 H), 6. 85 (m, 1 H), 7.35 (m, 2 H), 8.85-8. 90,9. 15-9.20, (3 X M, 8 H), 10.10 (s, 2 H).

3779-42-8, The synthetic route of 3779-42-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; DESTINY PHARMA LIMITED; SOLVIAS AG; WO2004/56828; (2004); A2;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI